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ABSTRACT  Malignant mesothelioma (MM) is a pleural malignant tumor that results 
predominantly from exposure to asbestos and has a poor prognosis. After a brief review of the 
epidemiology, etiology, and clinical status of MM, we detail methods being used to search for 
diagnostic and prognostic biomarkers for MM, particularly approaches involving the use of blood 
samples. The soluble mesothelin-related protein (SMRP), mesothelin/ERC and osteopontin 
are typical biomarkers for MM. In addition to these biomarkers, fibulin-3 has recently been 
introduced as a biomarker for MM. Furthermore, several molecules have been reported as 
useful biomarkers. In addition to an introduction outlining newer approaches such as those of 
proteomics, we hope to summarize the recent status of biomarkers for MM in this review.
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Introduction, epidemiology and etiology of MM
   Malignant mesothelioma (MM) is cancer 
occurring in the pleura, peritoneum, pericardium, 
as well as the tunica vaginalis testis1-3）. MM 
predominantly occurs in the pleura,  which 
represents more than 75% of MM cases. The 
frequency of deaths due to MM has been increasing 
in Japan. The number of MM deaths annually up to 
1999 was approximately 500, whereas the number 
of deaths since 2000 has been gradually increasing. 
According to the open-data from the Ministry of 
Health, Labour and Welfare, Japan, the number of 
deaths reached 1,410 in 2013 and comprised 1,121 
males and 289 females. The increase in the number 
of males was greater than that of females (Fig. 1)4,5）. 
The import and use of asbestos peaked in 1974 and 
relatively high amounts were imported up to the 
early 1990s. The curves of MM deaths show a late 
phase of 40 years relative to the asbestos use curve, 
and the number of deaths due to MM in Japan is 
expected to be approximately 100,000 between 
2025 and 20306,7）.
   The cause of MM is usually thought to be asbestos 
exposure8-10）, particularly in Japan. Although other 
minerals such as fibrous zeolite erionite cause MM, 
especially in the Cappadocia area of Turkey, these 
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areas, which include the Göreme National Park and 
Rock Site of Cappadocia, are registered as world 
heritage sites11）. In addition, ionizing radiation 
which causes DNA damage is also considered 
a partial cause of MM12,13）. Although the role of 
simian virus 40 (SV40) in the pathogenesis of 
MM has been discussed for considerable time, 
no definitive conclusion has been reached and 
researchers are still wondering whether there is 
a causal association between SV40 infection and 
MM12,14,15）. At the experimental level, there are 
some reports showing that nano-tubes cause MM in 
animal models16-18）. A study investigating differences 
between asbestos fibers and nano-tubes regarding 
their inclusion into cells18） basically revealed that 
firm and rigid fibrous substances with an aspect 
ratio of more than 3 may play a significant role in 
one of the carcinogenic mechanisms because the 
phagocytosis of these fibers physically interferes 
with cellular function such as spindle formation at 
mitosis. In addition, the chemical composition of 
these substances, particularly that of asbestos fibers, 
promotes cation exchange and induced continuous 
reactive oxygen species (RPS), which cause direct 
DNA damage12,19-21）.
 
Diagnosis and treatments for MM
   The clinical features of MM include a variety 
of respiratory symptoms such as chest pain, 
breathlessness and coughing, but there is no 
particular symptom that can be used to detect 
MM3,22-24）. Sometimes MM cases are suspected 
due to the chance discovery of pleural effusion 
without any symptoms, or a chance radiological 
examination that shows an abnormal shadow in 
the pleura. Various radiological examinations such 
as a  computed tomography (CT) scan, magnetic 
resonance imaging (MRI) and positron emission 
tomogrphy (PET)/CT should be performed once 
a MM case is suspected3,25-29）. A histological or 
cytological diagnosis should then be established. 
If there is pleural effusion, usually unilateral, an 
aspiration biopsy may be performed and recent 
immunohistochemical staining can be implemented 
Fig. 1.　Number of deaths from malignant mesothelioma in Japan (1995–2013). 
Reproduced using open-data from the web-site of the Ministry of Health, Labour and 
Welfare, Japan. The URL is as follows:
http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/tokusyu/chuuhisyu13/index.html
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using various antibodies such as calretinin, 
WT-1 and vimentin to detect MM with a high 
possibility 30-33）. One of the effective biopsy methods 
such as a CT-guided closed technique, biopsy under 
video-assisted thoracic surgery (VATS) or an open 
biopsy should then be performed34-36）.
   The common treatments of MM are surgery, 
systemic chemotherapy, radiotherapy, and combined 
poly-modal therapies38,39）. However, the prognosis 
of MM is still poor because of the difficulties 
of early diagnosis40-42）. The standard cytotoxic 
therapy such as cisplatin and pemetrexed yields 
a 20 to 40% response rate with approximately 12 
months overall survival43-48）. Various molecular 
targeting therapies for MM have been developed 
recently, such as anti-angiogenic therapies using 
monoclonal antibodies46,47）, targeting for mutated 
genes such as BRCA1 (breast cancer susceptibility 
gene I)-associated protein 1 (BAP1)48,49） and 
neurofibromatosis type 2 (NF2)50,51） genes by 
histone deacetylase (HDAC) inhibitors or signal-
transduction inhibitors. Moreover, immunotherapies 
targeting program death -1 (PD-1) or cytotoxic 
T-lymphocyte-associated antigen 4 (CTLA4) 
have been developed45）. Of course, various gene 
therapies52,53） including reduced expression in 
immortalized cells (REIC)/Dickkopf-related protein 
3 (Dkk3) gene have been developed54,55） and will 
form the basis of future trials.
Biomarkers for MM
   As mentioned above, since the prognosis of 
MM is still poor, diagnosis in the early stage is 
necessary in order for the early commencement of 
the various treatments. In this review, we introduce 
various candidates for diagnostic biomarkers of 
MM in serum and pleural effusion, although there 
are many prognostic biomarkers which have been 
investigated.  Basically various molecules expressed 
in pathological specimens and/or genes including 
micro RNAs expressed by mesothelioma cells are 
studying as the prognostic markers. 
1. Serum biomarkers for MM
1) Soluble mesothelin-related protein: SMRP56-59）
   Mesothelin is a glycoprotein attached to the 
cell surface of mesothelial cells and is involved in 
cell adhesion and cell-to-cell signaling. SMPR is 
an alternatively spliced form of mesothelin, and 
this variant is secreted from mesothelioma cells 
into extracellular spaces. The elevation of SMRP 
can therefore be detected in serum. Robinson et 
al. reported that SMPR can be used for the early 
detection and monitoring of disease progression 
of MM i n Australian patients. The reported 
sensitivity and specificity are approximately 80 and 
90%, respectively. There are also several reports 
investigating the use of SMRP to detect and monitor 
MM in Japan60,61）.
2) Mesothelin/ERC62-65）
   The ERC (expressed in renal carcinoma) gene 
was identified following investigation of Eker rat 
renal carcinoma, and is identified as a homolog 
of the human mesothelin gene. The product of the 
human mesothelin gene is cleaved by protease and 
the N-terminal fragment (N-ERC) is secreted into 
the blood. Hino et al. reported the development of 
an enzyme-linked immunosorbent assay (ELISA) 
system for the detection of N-ERC/mesothelin and 
demonstrated its usefulness for early diagnosis. It 
should be added that SMRP and N-ERC/mesothelin 
are also detected in cases of ovarian cancer.
3) Osteopontin66-68）
   Osteopontin (OPN), also known as bone 
sialoprotein I (BSP-1 or BNSP), early T-lymphocyte 
activation (ETA-1), secreted phosphoprotein 1 
(SPP1), 2ar and Rickettsia resistance (Ric), is a 
glycoprotein and functions in biomineralization, 
bone remodeling, immune reactions such as 
chemotaxis, and cell adhesion. Although an elevated 
serum level of OPN has been reported in various 
tumors including lung, breast, gastro-intestinal and 
ovarian cancers, higher serum levels of OPN in MM 
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have also been reported with high sensitivity and 
specificity. However, its effectiveness for the early 
diagnosis of MM remains unconfirmed and requires 
further study.
4) Fibulin-369-71）
   Recent methods to identify biomarkers of 
some diseases have made use of specialized and 
comprehensive searching methods such as those 
involving cDNA microarrays and proteomics. It was 
mentioned previously that OPN was identified using 
the cDNA microarray method, and the same group 
also demonstrated in a similar way that fibulin-3 
is a biomarker for MM. According to their report, 
the serum fibulin-3 level can be used to distinguish 
asbestos-exposed patients without MM and the early 
(stage I and II) stages of MM. 
5) Soluble syndecan-172）
   Syndecan-1 (CD138) is a cell surface proteoglycan 
that plays a role in cell proliferation, differentiation, 
invasion migration and angiogenesis. The cellular 
expression as assayed by an immunohistochemical 
method is reported to distinguish adenocarcinoma 
from MM. The soluble form of syndecan-1 in serum 
was then proposed as a diagnostic and prognostic 
factor for MM.
6) Circulating fibrinogen73）
   Fibrinogen is an acute phase response protein 
for inflammation and is produced by the liver in 
response to pro-inflammatory cytokines similar to 
the C-reactive protein (CRP). Ghanim et al. reported 
that plasma circulating fibrinogen is a prognostic 
and predictive biomarker for MM. Although its 
sensitivity and specificity for the detection of MM 
and its value as a prognostic factor for overall 
survival in MM are not very high, it may be useful 
since plasma fibrinogen levels are usually measured 
during common medical screening for various 
diseases.
7) RANTES74）
   RANTES/CCL5 (chemokine (C-C motif) ligand 5) 
is a C-C chemokine associated with allergic immune 
reactions and immunomodulation in cancer. Comar 
et al. reported elevated levels of RANTES and 
CTACK (CCL27; chemokine (C-C motif) ligand 
27) in asbestos-handling workers and MM patients 
using a magnetic bead multiplex immunoassay for 
47 analytes including cytokines and growth factors. 
Although they reported significant differences 
in serum RANTES levels between asbestos-
handling workers and MM patients, both groups 
showed overlapping increased levels of RANTES. 
However, this type of immunological approach may 
be important because tumor markers produced by 
malignant cancer cells have some limitation and 
depend on tumor volume, although early detection is 
therefore sometimes difficult using these products.
8) Hyaluronan75）
   Hyaluronan/hyaluronic  ac id  i s  a  l inear 
polysaccharide associated with mesothelioma. 
Although hyaluronic acid is the classical marker 
for the detection of MM in pleural effusion76,77）, the 
serum level of hyaluronan shows less sensitivity for 
the detection of MM. Mundt et al. presented specific 
two-step prediction methods using hyaluronan and 
N-ERC/mesothelin. Using several markers to detect 
MM will be a valuable approach to increase the 
specificity and sensitivity of the detection process.
9) YKL-40/chitinase-3-like-178）
   Corradi et al. reported that MM patients showed 
significantly higher serum levels of mesothelin, 
YKL-40, interleukin (IL)-8 and vascular endothelial 
growth factor (VEGF) compared to healthy controls. 
Higher levels of significance were obtained for 
mesothelin and YKL-40. However, their analysis 
did not distinguish MM from non-small cell lung 
cancer. Further analysis may be needed to clarify 
the effectiveness of this approach.
10) Newer approaches to identify biomarkers
i) Proteomics-based surveillance tool79）
   Ostroff et al. used a proteomics-based method 
and identified 13 genes/proteins with statistical 
significance between a control population and 
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pathogenic stages (I to IV) in MM using serum. 
They found that four proteins are significantly 
decreased in MM compared with healthy controls, 
namely, apolipoprotein A-I, fibronectin, KIT/
stem cell factor receptor and kallistatin. Proteins 
showing significantly increased levels include 
C9 (complement component 9), C23 (chemokine 
(C-C motif) ligand 23), CDK5/CDK5R1 complex 
(cyclin-dependent kinase 5-/cyclin-dependent 
kinase 5, regulatory subunit 1 (p35) complex), 
CXCL13 (chemokine (C-X-C motif) ligand 13), F9 
(coagulation factor IX), FCN2 (ficolin (collagen/
fibrinogen domain containing lectin) 2), ICAM2 
(intercellular adhesion molecule 2), MDK (midkine) 
and TNFRSF8 (CD30). Although most of the 
proteins have to be validated by other investigations, 
this type of newer approach may be useful in 
identifying unexpected molecules associated with 
mesothelioma and asbestos pathophysiology.
ii) Selected reaction monitoring (SRM) assay80）
   Cerciello et al. claim to have identified a seven 
glycoprotein signature for MM in serum. They 
used selected reaction monitoring (SRM) assay 
technology, which relies on the ability of a triple 
quadrupole mass spectrometer (QQQ) to selectively 
isolate predefined peptides of interest in a complex 
protein mixture after enzymatic digestion. In 
addition to the seven glycoprotein signature, they 
identified candidate biomarkers of MM extracted by 
the SRM assay. The candidates with a concentration 
above 102 ng/ml include hemopexin, paraoxonase/
anylesterase 1,  attractin, thrombospondin-1, 
galectin-3-binding protein and basement membrane-
specific heparin sulfate proteoglycan core protein. 
Candidate proteins with a concentration near 102 
ng/ml include vasorin, ICAM-1 (intracellular 
adhesion molecule), phospholipid transfer protein, 
laminin subunit gamma-1 and CD44 antigen. The 
concentrations of candidates in this group are 
similar to those of hyaluronic acid, fibulin-3 and 
osteopontin. Although these candidates were not 
matched by the above-mentioned Ostroff report, this 
kind of approach will yield new insights regarding 
the search for biomarkers.
iii) Surface imprinting for detection of biomarkers81）
   Mathur et al. reported development of a biosensor 
for the detection of a MM biomarker using surface 
imprinting and utilized hyaluronan-linked protein 
1 (HAPLN1), which has been shown to be highly 
expressed in mesothelioma cells. They employed 
an amplifying detection method using surface 
imprinting. This approach is also important for 
the modification of detection methods for known 
molecules.
2. Biomarkers for MM in pleural effusion82-85）
   Among the above-mentioned biomarkers, SMRP, 
N-ERC/mesothelin, OPN, fibulin-3 and hyaluronic 
acid are candidates for early diagnostic biomarkers 
of MM. 
3. Immunological alterations caused by asbestos 
exposure and their use as biomarkers for MM
   Our group has been investigating the effects of 
asbestos exposure on human immune competent 
cells. We found that Cd4+ T cells showed reduction 
of surface expression of CXCR3 (Chemokine 
(C-X-C motif) receptor 3) and suppressed capacity 
for interferon (IFN)-γ production86,87）. Natural 
killer (NK) cells represent one of the activation 
receptors for NK cells, and our research revealed 
reduced expression of NKp46 on the cell surface 
of freshly isolated NK cells from MM patients88,89）. 
Our group has recently been utilizing a magnetic 
bead multiplex immunoassay using plasma derived 
from asbestos-exposed patients with either pleural 
plaque or MM. Taken together with findings 
concerning alteration of cell surface molecules and 
RNA expression, these approaches will form the 
basis of a multi-factor detection assay for asbestos 
exposure and individuals with MM90,91）.
Conclusion
   This review details approaches concerning the 
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detection of diagnostic and prognostic biomarkers 
for MM. In Japan, the high-risk population for 
asbestos exposure includes people who have lived 
near asbestos-handling manufacturers, workers 
involved in building demolition, and individuals 
handling rubble due to earthquake and other 
disasters, and the screening methods used to 
detect asbestos exposure and MM still depend on 
radiological methods. However, issues regarding 
radiological exposure and the acceptable frequency 
of these examinations indicate this approach may 
not be suitable for the detection of MM. Screening 
methods that utilize peripheral blood and other body 
materials such as urine, saliva, hair and exhaled 
breath should therefore be developed and validated 
in the near future.
   We have not mentioned newer findings regarding 
recently developed molecules for the pathological 
diagnosis of MM or prognostic marker genes 
including microRNAs (miRNA) specifically 
expressed or showing altered epigenetic status 
in MM tumor cells. However, a consideration of 
these aspects with the exploration of serum/plasma, 
effusion biomarkers, and the development of gene 
and molecular expression profiles of mesothelioma 
cells will result in the rapid development of 
detection methods that will help MM patients obtain 
a better prognosis.
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